危重型新型冠状病毒肺炎合并2型糖尿病患者治疗用药评价与药学监护策略  

Drug evaluation and pharmaceutical monitoring strategies in the care of a critically ill Corona Virus Disease-2019 patient complicated with type 2 diabetes mellitus

作　　者：王颖[1] 朱昆[1] WANG Ying;ZHU Kun(Department of Pharmacy,China-Japan Union Hospital of Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院药学部,长春130033

出　　处：《药学服务与研究》2020年第3期164-168,共5页Pharmaceutical Care and Research

基　　金：中国药学会全国医药经济信息网科技传播创新工程(CMEI2020KPYJ00417)。

摘　　要：目的:评价1例危重型新型冠状病毒肺炎合并2型糖尿病患者的治疗用药方案并提出药学监护策略。方法:运用临床药理学、药效学知识及药品不良反应监测评价等方法对该患者的用药方案进行分析和评价,结合病情和用药提出药学监护策略。结果:对该患者的探索性药物治疗基本符合新型冠状病毒肺炎诊疗方案。结论:新型冠状病毒肺炎进展迅速,合并糖尿病等慢性病的患者临床表现更为复杂,尤其是合并使用了影响血糖的药物,治疗方案需重视患者的血糖管理。Objective:To evaluate treatment profiles in the care of a critically ill Corona Virus Disease-2019(COVID-19)patient complicated with type 2 diabetes mellitus,and also to propose pharmaceutical monitoring strategies for the patient.Methods:By using the medical knowledge of clinical pharmacology and pharmacodynamics,as well as adverse drug reaction monitoring,treatment profiles were analyzed and evaluated,and then pharmaceutical monitoring strategies were proposed in accordance with the conditions and medication of the patient.Results:The exploratory treatment of the patient was on the whole in line with the diagnosis and treatment profiles of COVID-19.Conclusion:COVID-19 progresses very rapidly,and the clinical manifestations of COVID-19 patients combined with such chronic diseases as diabetes mellitus are usually more complex,which is especially the case when the patients take drugs which could affect blood glucose.More attention should be paid to blood glucose management in treatment strategies for such patients.

关 键 词：新型冠状病毒肺炎 危重型 糖尿病 2型 用药评价 药学监护 

分 类 号：R978.7[医药卫生—药品] R969.3[医药卫生—药学]